CEO Silverman purchases 100,000 shares (100.0K) across 3 trades at $0.78–$0.83 for $80,476.00 total amid -27.8% 30-day decline.
Joshua Silverman, CEO and President of PharmaCyte Biotech, executed 3 separate purchases totaling 100,000 shares for $80,476.00, raising his stake by 31.6% from 316,250 to 416,250 shares. The purchases occurred at prices ranging from $0.78 to $0.83, during a period when the stock has declined 27.8% over 30 days and trades 54.1% below its 52-week high of $1.81. The company is currently unprofitable (net income $-7,417,975.00) with zero quarterly revenue and a market cap of $8,411,352.80. The CEO's accumulation at declining prices, while the company faces significant operational headwinds, presents a pattern that merits scrutiny of both the business fundamentals and management's rationale for the deployment of capital at this valuation.